Genentech and Plexxikon have applied for market approval with the FDA for their jointly developed skin cancer drug, vemurafenib or PLX4032. The drug has been shown to extend lives of melanoma patients in clinical trials. Roche has also submitted an application in the European Union.
Plexxikon has agreed to be acquired by Daiichi Sankyo for $805 million to bost the latter's cancer portfolio. See Xconomy.
Posted by Bruce Lehr May 11th 2011.